Steven Prestrelski
Principal investigator, leads Xeris Pharmaceuticals, Inc..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$8.2MFederal grants as PI9 awards
1Patents grantedLatest Jan 6, 2026
60Papers5,058 citations
Federal awards and patents by year
AwardsPatents
9 awards · $8.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 23, 2018 | NIH | SBIR Phase II Auto-Injectable Diazepam Formulation for Rapid Treatment of Uncontrolled Seizures | $794K | Xeris Pharmaceuticals, Inc. |
| Sep 15, 2017 | NIH | SBIR Phase II Auto-Injectable Diazepam Formulation for Rapid Treatment of Uncontrolled Seizures | $1.6M | Xeris Pharmaceuticals, Inc. |
| Aug 17, 2017 | NIH | SBIR Phase II CSI Glucagon for Treatment of Congenital Hyperinsulinism | $755K | Xeris Pharmaceuticals, Inc. |
| Jul 6, 2017 | NIH | SBIR Phase II Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia | $405K | Xeris Pharmaceuticals, Inc. |
| Sep 1, 2016 | NIH | SBIR Phase II CSI Glucagon for Treatment of Congenital Hyperinsulinism | $1.6M | Xeris Pharmaceuticals, Inc. |
| Jul 10, 2016 | NIH | SBIR Phase II Closed Loop Glucagon Pump for Treatment of Post Bariatric Hypoglycemia | $1.2M | Xeris Pharmaceuticals, Inc. |
| Jul 8, 2016 | NIH | SBIR Phase II Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia | $816K | Xeris Pharmaceuticals, Inc. |
| Jun 16, 2015 | NIH | SBIR Phase II Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia | $562K | Xeris Pharmaceuticals, Inc. |
| Mar 24, 2015 | NIH | SBIR Phase II CSI Glucagon for Treatment of Congenital Hyperinsulinism | $485K | Xeris Pharmaceuticals, Inc. |
2 patents as inventor
- US 12514907Xeris Pharmaceuticals, Inc.Jan 6, 2026
- US Xeris Pharmaceuticals, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#106
Awards as PI#151
Patents#155
Companies
- Xeris Pharmaceuticals, Inc.Leads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.